Coatbridge Service Centre welcomes Frank Mcnally, MP

On Friday 17 January we welcomed Frank McNally, MP  for Coatbridge & Bellshill to the Coatbridge Service Centre to meet the team. Our Managing Director Marie Evans and Scott Balfour, Coatbridge Service Centre Manager showed how our 350+ team members at Scotland support the NHS and community pharmacy. As part of the warehouse tour Frank saw colleagues work together to fulfil customer orders and create healthier futures. 

Marie Evans, Managing Director, Alliance Healthcare UK said: “It was great to meet Frank and we are very grateful for his time to visit the Coatbridge team and hear more about our business. The scale of the operation at Coatbridge is so impressive and the team continue to deliver a terrific service for the patient and demonstrate how we are united in our responsibility to create healthier futures.”

Reflecting on the Vantasy Football Tournament

Alliance Healthcare Drivers take part in the inaugural Vantasy Football Tournament — a five-a-side event aimed at uniting van drivers and addressing mental health concerns.

Last year, Alliance Healthcare partnered with Mercedes-Benz Vans and ex-Sky Sports pundit Chris Kamara at the Vantasy Football tournament—a five-a-side event aimed at uniting van drivers and addressing mental health concerns.

The Summer tournament provided an essential platform for van drivers, who often face isolation on the road, to get together for a day of sport and offer them the opportunity to speak with other drivers who may have faced the same struggles. The Under the Bonnet report revealed that van drivers can spend up to 25 hours a week alone, with many engaging in only a handful of conversations daily. This event highlighted the urgent need for connection among these drivers.

Prior to the tournament, a team of Alliance Healthcare delivery drivers participated in a coaching session with Chris Kamara, fostering both football skills and open discussions about mental health. The tournament itself was filled with laughter and camaraderie, showcasing the role of sports in building community and supporting wellbeing.

Paul Graham, Senior Driver Team Manager, Alliance Healthcare UK, said: “Coming to an event like this gives us a chance to wind down, to get to know each other a bit more [so} we can open up. Over dinner we were talking about our mental health struggles with each other - the event has been really positive”

Check out the below video capturing the all the highlights and excitement from the tournament, which serves as a reminder that no one has to face their challenges alone. 👇

Class 2 Recall - ALMUS DRY COUGH RELIEF 200ML

CLASS 2 RECALL

Bells Healthcare Limited on ALMUS DRY COUGH RELIEF 200ML

• MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-tesco-health-dry-cough-relief-200ml-asda-strong-dry-tickly-cough-200ml-almus-dry-cough-relief-and-bells-dual-action-dry-cough-el-25-a-slash-03?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=e435ef37-e02b-4503-bf1b-66b46e4dabfd&utm_content=immediately

• MHRA ref: DMRC-34222471

Further information

For medical information enquiries please contact: Trevor Price, QPPV, trevor.price@bells-healthcare.com

For stock control enquiries please contact: Chris Bracken chris.bracken@bells-healthcare.com

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Alliance Healthcare will only be accepting  returns against the Almus livery that we stock.

Class 4 caution in use-Irbesartan 150mg & 300mg Tablets

Jubilant Pharmaceuticals NV has informed the MHRA that the Patient information leaflet (PIL) in the cartons for the batches listed in this notification include an outdated PIL.

MHRA Drug alert date: 13th January 2025

MHRA Drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-irbesartan-150-mg-and-300-mg-film-coated-tablets-el-25-a-slash-02?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ba29731f-c857-4e43-9347-5e2d5baeafc8&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact: safety.uk@lambda-cro.com, Telephone number: 0080089013370

For stock control enquiries please contact: JPUK.Customerservice@jubl.com, Telephone: +4401233 552293

Class 4 caution in use-Rabeprazole sodium 10 & 20mg GR tablets

Bristol Laboratories Limited has informed the MHRA that the Patient Information Leaflet (PIL) in the batches in the table for Rabeprazole sodium 10mg and 20mg gastro-resistant tablets do not contain the most up to date safety information.

MHRA Drug alert date: 9th January 2025

MHRA drug alert link https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-rabeprazole-sodium-10mg-and-20mg-gastro-resistant-tablets-el-25-a-slash-01?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=2ea2f68a-a589-4a59-9548-7c91851e5608&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact at: email: info@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

For stock control enquiries please contact at email: notifications@bristol-labs.co.uk, or telephone: +44 (0) 1442 200 922

Paula Sutherland Appointed Sales Director at Alliance Healthcare UK

Alliance Healthcare UK is pleased to announce that Paula Sutherland has been appointed to the position of Sales Director. Paula will lead sales teams in delivering products and services to community pharmacies. Her leadership will ensure that Alliance Healthcare offerings align with the unique needs of these pharmacies and, ultimately, the patients they serve.

Paula will lead Alliance Healthcare’s UK sales teams, ensuring that the business’ product offerings align with the unique needs of these pharmacies and, ultimately, the patients they serve.

Paula has been a key figure at Alliance Healthcare since 2012, holding leadership roles that have focused on building strong relationships with community pharmacies, manufacturer partners, and hospital services.

Paula's extensive experience will be instrumental in further strengthening Alliance Healthcare’s partnerships with community pharmacies, which often serve as the first point of contact for patients seeking medical advice and treatment. By leveraging her insights and relationships, she will ensure that our products and services not only meet the demands of the market but also empower pharmacies to thrive as essential health resources in their communities.

Before joining Alliance Healthcare, Paula gained valuable experience in commercial roles within the fast-moving consumer goods sector, at companies such as Perrigo UK and global supply-chain logistics company CHEP.

Paula Sutherland, Sales Director, said: “I am delighted to step into this position at such an exciting time for Alliance Healthcare, and at such a pivotal moment for the sector. Pharmacists play a vital role in local communities up and down the country yet face some of the most challenging circumstances, and I look forward to working closely with our expert field team to listen and enhance our proposition for our pharmacy customers. By ensuring that community pharmacies are well-supported, we can create healthier communities and enhance the quality of care for all patients.”

Marie Evans, Managing Director at Alliance Healthcare said: “Paula has been an invaluable part of the Alliance Healthcare team, demonstrating exceptional leadership and dedication in every role she has undertaken. Pharmacy relationships are an integral part of our business, and Paula’s deep understanding of the pharmacy landscape and ability to foster strong partnerships makes her the ideal person to lead our teams going forwards.”

Class 4 caution in use-Vyvgart 1000mg solution for injection

Argenx BV have informed MHRA that the Patient Information Leaflet (PIL) in the affected packs incorrectly contains reference to two subcutaneous injection sites. Only subcutaneous injection to the abdomen is permitted.

MHRA Drug alert date: 19th December 2024

MHRA drug alert link:https://www.gov.uk/drug-device-alerts/class-4-medicines-notification-argenx-bv-vyvgart-1000-mg-solution-for-injection-el-24-a-slash-63?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=ab2d5607-6db9-4cc3-9766-16136bc8802d&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact ukmedinfo@argenx.com or +44 (0)20 4532 4016.

For stock control enquiries please contact rpi@argenx.com or +44 (0)7801 748936.

Field Safety notice-Various AMS dressings

We have received a field safety notice from Advanced Medical Solutions (AMS) regarding batches of various dressings

Date of recall:17/12/24

Please return all affected stock to your original supplier for credit. Unfortunately we can only accept stock purchased from us (Alliance Healthcare Distribution Limited). Any other stock will be returned to your stores/Pharmacies.

Please note that anything not returned to us, or notified to us, within 3 months of this notification, cannot be reimbursed by way of a credit.

Class 2 Recall-WockAIR 160 microgram/4.5 microgram, inhalation powder

Wockhardt UK Limited is recalling this batch as a precautionary measure following the identification of a low number of units which may have a defect in the 'top case' resulting in a dose not being able to be dispensed.

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-2-medicines-recall-wockhardt-uk-limited-wockair-160-microgram-slash-4-dot-5-microgram-inhalation-powder-el-24-a-slash-62?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=196509da-279d-4663-b40b-c3c0cadad8aa&utm_content=immediately

Further information

For medical information enquiries please telephone 01978 661261 and ask for ‘drug safety’, or email drug.safety@wockhardt.co.uk.

For stock control enquiries please telephone 01978 661261 and ask for ‘customer services’, or email group_uk_csu@wockhardt.co.uk.

Please return all affected stock to your original supplier for credit. Unfortunately, we can only accept stock purchased from us (Alliance Healthcare Distribution Limited).

Please note that anything not returned to us, or notified to us, within 12 weeks of this notification, cannot be reimbursed by way of a credit.

Class 4 caution in use-Liothyronine Sodium tablets 5mcg and 20mcg

Strides Pharma UK Ltd has informed MHRA of an error in the patient information leaflet (PIL) for Liothyronine Sodium 20 micrograms Tablets and Liothyronine Sodium 5 micrograms Tablets.

MHRA Drug alert date: 28th November 2024

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-strides-pharma-uk-ltd-liothyronine-sodium-5-and-20-micrograms-tablets-el-24-a-slash-58?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=1b6cc57b-c4b2-4d42-b911-de0ebf43fd1b&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For medical information enquiries please contact Strides Pharma UK Ltd via email dl-drugsafety@strides.com or telephone +919844460742

For stock control enquiries please contact Strides Pharma UK Ltd via email customerservicesuk@stridespharma.co.uk or telephone 01923 255580